Zolbetuximab, a monoclonal antibody that targets CLDN18.2, was recently given approval as a 1st-line treatment for HER2-negative, CLDN18.2-positive advanced gastric cancer, and represents a new direction in molecular-targeted therapy for this disease.3) This evidence concerns the gene ERBB2 and gastric cancer.